The role of radiotherapy and chemoradiation in the management of primary liver tumours

Clinical Oncology

Volumn 26, Issue 9, 2014, Pages 569-580

  Aitken, K L ^a   Hawkins, M A ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cholangiocarcinoma; External beam radiotherapy; Hepatocellular carcinoma; Stereotactic body radiotherapy

Indexed keywords

CAPECITABINE; FLOXURIDINE; SORAFENIB; SUNITINIB;

ARTICLE; BILE DUCT CARCINOMA; CANCER CONTROL; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; CHILD PUGH SCORE; CHRONIC LIVER DISEASE; COMPUTER ASSISTED RADIOTHERAPY; CRYOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; ION THERAPY; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER METASTASIS; LIVER TRANSPLANTATION; LIVER TUMOR; LOCAL THERAPY; MAINTENANCE THERAPY; MICROWAVE RADIATION; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTON THERAPY; RADIATION DOSE FRACTIONATION; RADIOFREQUENCY ABLATION; RADIOSENSITIVITY; RECURRENCE RISK; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMIC THERAPY; TREATMENT PLANNING; UNITED KINGDOM; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS;

CARCINOMA, HEPATOCELLULAR; CHEMORADIOTHERAPY; HUMANS; LIVER NEOPLASMS; RADIOTHERAPY, CONFORMAL;

EID: 84905573674     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.05.016     Document Type: Article

References (102)

1. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J 2009, 339:b2535.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
3. Statistics CCI Liver cancer incidence statistics 2013.
4. Center M.M., Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2011, 20:2362-2368.
5. Klein J., Dawson L.A. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 2013, 87:22-32.
6. Lock M.I., Hoyer M., Bydder S.A., et al. An international survey on liver metastases radiotherapy. Acta Oncol 2012, 51:568-574.
7. Dawson L.A. Overview: Where does radiation therapy fit in the spectrum of liver cancer local-regional therapies?. Semin Radiat Oncol 2011, 21:241-246.
8. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255.
9. Llovet J.M., Schwartz M., Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25:181-200.
10. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
11. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
12. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
13. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
14. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
15. Guha C., Kavanagh B.D. Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol 2011, 21:256-263.
16. Cheng J.C., Wu J.K., Lee P.C., et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2004, 60:1502-1509.
17. Liang S.X., Zhu X.D., Lu H.J., et al. Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer 2005, 103:2181-2188.
18. Pan C.C., Kavanagh B.D., Dawson L.A., et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010, 76:S94-S100.
19. Liu M.T., Li S.H., Chu T.C., et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol 2004, 34:532-539.
20. Ben-Josef E., Normolle D., Ensminger W.D., et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005, 23:8739-8747.
21. Mornex F., Girard N., Beziat C., et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies -mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006, 66:1152-1158.
22. Kim T.H., Kim D.Y., Park J.W., et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 2006, 29:568-575.
23. Seong J., Lee I.J., Shim S.J., et al. A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int 2009, 29:147-152.
24. Oh D., Lim do H., Park H.C., et al. Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity. Am J Clin Oncol 2010, 33:370-375.
25. Huang B.S., Tsang N.M., Lin S.M., et al. High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: tumor responses and toxicities. Oncol Lett 2013, 6:1514-1520.
26. Seo Y.S., Kim J.N., Keum B., et al. Radiotherapy for 65 patients with advanced unresectable hepatocellular carcinoma. World J Gastroenterol 2008, 14:2394-2400.
27. Dawson L.A., Normolle D., Balter J.M., McGinn C.J., Lawrence T.S., Ten Haken R.K. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002, 53:810-821.
28. Mendez Romero A., Wunderink W., Hussain S.M., et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol 2006, 45:831-837.
29. Choi B.O., Choi I.B., Jang H.S., et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer 2008, 8:351.
30. Louis C., Dewas S., Mirabel X., et al. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat 2010, 9:479-487.
31. Seo Y.S., Kim M.S., Yoo S.Y., et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 2010, 102:209-214.
32. Kwon J.H., Bae S.H., Kim J.Y., et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010, 10:475.
33. Price T.R., Perkins S.M., Sandrasegaran K., et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer 2012, 118:3191-3198.
34. Andolino D.L., Johnson C.S., Maluccio M., et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011, 81:e447-e453.
35. Kang J.K., Kim M.S., Cho C.K., et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012, 118:5424-5431.
36. Huang W.Y., Jen Y.M., Lee M.S., et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012, 84:355-361.
37. Bibault J.E., Dewas S., Vautravers-Dewas C., et al. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One 2013, 8:e77472.
38. Bujold A., Massey C.A., Kim J.J., et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013, 31:1631-1639.
39. Yoon S.M., Lim Y.S., Won H.J., et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012, 82:2004-2011.
40. Cardenes H.R., Price T.R., Perkins S.M., et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010, 12:218-225.
41. Georgiades C.S., Hong K., D'Angelo M., Geschwind J.F. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005, 16:1653-1659.
42. Han K.H., Seong J., Kim J.K., Ahn S.H., Lee do Y., Chon C.Y. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008, 113:995-1003.
43. Rim C.H., Yang D.S., Park Y.J., Yoon W.S., Lee J.A., Kim C.Y. Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis. Jpn J Clin Oncol 2012, 42:721-729.
44. Chuma M., Taguchi H., Yamamoto Y., et al. Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. J Gastroenterol Hepatol 2011, 26:1123-1132.
45. Katamura Y., Aikata H., Takaki S., et al. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol 2009, 44:492-502.
46. Zhang X.B., Wang J.H., Yan Z.P., Qian S., Du S.S., Zeng Z.C. Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. Cancer 2009, 115:1245-1252.
47. Toya R., Murakami R., Baba Y., et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol 2007, 84:266-271.
48. Lin C.S., Jen Y.M., Chiu S.Y., et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 2006, 36:212-217.
49. Kim D.Y., Park W., Lim D.H., et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005, 103:2419-2426.
50. Zeng Z.C., Fan J., Tang Z.Y., et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005, 61:432-443.
51. Yamada K., Izaki K., Sugimoto K., et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003, 57:113-119.
52. Ishikura S., Ogino T., Furuse J., et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002, 25:189-193.
53. Tazawa J., Maeda M., Sakai Y., et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001, 16:660-665.
54. Tanaka Y., Nakazawa T., Komori S., et al. Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes. J Gastroenterol Hepatol 2013 Jul 22.
55. Xi M., Zhang L., Zhao L., et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013, 8:e63864.
56. Kim J.Y., Yoo E.J., Jang J.W., Kwon J.H., Kim K.J., Kay C.S. Hypofractionated radiotherapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Radiat Oncol 2013, 8:15.
57. Tang Q.H., Li A.J., Yang G.M., et al. Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study. World J Surg 2013, 37:1362-1370.
58. Meng M.B., Cui Y.L., Lu Y., et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2009, 92:184-194.
59. McIntosh A., Hagspiel K.D., Al-Osaimi A.M., et al. Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. Cancer 2009, 115:5117-5125.
60. Chi K.H., Liao C.S., Chang C.C., et al. Angiogenic blockade and radiotherapy in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010, 78:188-193.
61. Dawson L.A., Brade A., Cho C., et al. Phase I study of sorafenib and SBRT for advanced hepatocellular carcinoma. Am Soc Radiat Oncol 2012, 84:S10-S11.
62. Skinner H.D., Hong T.S., Krishnan S. Charged-particle therapy for hepatocellular carcinoma. Semin Radiat Oncol 2011, 21:278-286.
63. Bush D.A., Kayali Z., Grove R., Slater J.D. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer 2011, 117:3053-3059.
64. Hashimoto T., Tokuuye K., Fukumitsu N., et al. Repeated proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006, 65:196-202.
65. Seong J., Koom W.S., Park H.C. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int 2005, 25:261-265.
66. Soliman H., Ringash J., Jiang H., et al. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J Clin Oncol 2013, 31:3980-3986.
67. Feng M., Smith D.E., Normolle D.P., et al. A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy. Int J Radiat Oncol Biol Phys 2012, 83:1441-1447.
68. Hong T.S. Radiotherapy for hepatocellular carcinoma with tumor vascular thrombus: ready for prime time?. J Clin Oncol 2013, 31:1619-1620.
69. Hong T.S., Crane C.H., Dawson L.A. Interobserver variability in target definition for hepatocellular carcinoma (HCC) with and without portal vein thrombosis: Radiation Therapy Oncology Group (RTOG) HCC Consensus Panel. Am Soc Radiat Oncol 2013, 87:S28.
70. Al Hamad A.A., Hassanain M., Michel R.P., Metrakos P., Roberge D. Stereotactic radiotherapy of the liver: a bridge to transplantation. Technol Cancer Res Treat 2009, 8:401-405.
71. Katz A.W., Chawla S., Qu Z., Kashyap R., Milano M.T., Hezel A.F. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys 2012, 83:895-900.
72. Khan S.A., Davidson B.R., Goldin R.D., et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012, 61:1657-1669.
73. Wakai T., Shirai Y., Moroda T., Yokoyama N., Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer 2005, 103:1210-1216.
74. Nathan H., Pawlik T.M., Wolfgang C.L., Choti M.A., Cameron J.L., Schulick R.D. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 2007, 11:1488-1496.
75. Kloek J.J., Ten Kate F.J., Busch O.R., Gouma D.J., van Gulik T.M. Surgery for extrahepatic cholangiocarcinoma: predictors of survival. HPB (Oxford) 2008, 10:190-195.
76. Jarnagin W.R., Ruo L., Little S.A., et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003, 98:1689-1700.
77. Darwish Murad S., Kim W.R., Harnois D.M., et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012, 143:88-98. e83; quiz e14.
78. Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362:1273-1281.
79. Vern-Gross T.Z., Shivnani A.T., Chen K., et al. Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys 2011, 81:189-198.
80. Shinohara E.T., Mitra N., Guo M., Metz J.M. Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys 2009, 74:1191-1198.
81. Shinohara E.T., Mitra N., Guo M., Metz J.M. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008, 72:1495-1501.
82. Todoroki T., Ohara K., Kawamoto T., et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000, 46:581-587.
83. Gerhards M.F., van Gulik T.M., Gonzalez Gonzalez D., Rauws E.A., Gouma D.J. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 2003, 27:173-179.
84. Stein D.E., Heron D.E., Rosato E.L., Anne P.R., Topham A.K. Positive microscopic margins alter outcome in lymph node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy. Am J Clin Oncol 2005, 28:21-23.
85. Figueras J., Llado L., Valls C., et al. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transpl 2000, 6:786-794.
86. Hughes M.A., Frassica D.A., Yeo C.J., et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007, 68:178-182.
87. Kim S., Kim S.W., Bang Y.J., Heo D.S., Ha S.W. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2002, 54:414-419.
88. Nelson J.W., Ghafoori A.P., Willett C.G., et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2009, 73:148-153.
89. Veeze-Kuijpers B., Meerwaldt J.H., Lameris J.S., van Blankenstein M., van Putten W.L., Terpstra O.T. The role of radiotherapy in the treatment of bile duct carcinoma. Int J Radiat Oncol Biol Phys 1990, 18:63-67.
90. Grove M.K., Hermann R.E., Vogt D.P., Broughan T.A. Role of radiation after operative palliation in cancer of the proximal bile ducts. Am J Surg 1991, 161:454-458.
91. Crane C.H., Macdonald K.O., Vauthey J.N., et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002, 53:969-974.
92. Brunner T.B., Schwab D., Meyer T., Sauer R. Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis. Strahlenther Onkol 2004, 180:751-757.
93. Chen Y.X., Zeng Z.C., Tang Z.Y., et al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer 2010, 10:492.
94. Ghafoori A.P., Nelson J.W., Willett C.G., et al. Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2011, 81:654-659.
95. Alden M.E., Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994, 28:945-951.
96. Deodato F., Clemente G., Mattiucci G.C., et al. Chemoradiation and brachytherapy in biliary tract carcinoma: long-term results. Int J Radiat Oncol Biol Phys 2006, 64:483-488.
97. Herfarth K.K., Debus J., Lohr F., et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001, 19:164-170.
98. Tse R.V., Hawkins M., Lockwood G., et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008, 26:657-664.
99. Goodman K.A., Wiegner E.A., Maturen K.E., et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010, 78:486-493.
100. Kopek N., Holt M.I., Hansen A.T., Hoyer M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010, 94:47-52.
101. Polistina F., Costantin G., Casamassima F., et al. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010, 17:2092-2101.
102. Barney B.M., Olivier K.R., Miller R.C., Haddock M.G. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 2012, 7:67.